<DOC>
	<DOC>NCT01878669</DOC>
	<brief_summary>The aim of this study is to evaluate the effects of N-acetyl cysteine on periprocedural myocardial infarction and major cardiac and cerebral events in patients undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy.</brief_summary>
	<brief_title>Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Patients &gt; 18 years old undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy (Mehran Score â‰¥ 5) Primary percutaneous coronary intervention Low risk for contrast induced nephropathy (Mehran Score &lt; 5) Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...) Infection Pregnancy, Lactation Renal failure requiring dialysis Hepatic failure History allergy for NAC History of Asthma Chronic nitrate usage Malignancy Use of corticosteroids Leukocytosis,Thrombocytosis,Anemia Blood pressure of &gt;180/100mmHg despite antihypertensive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>n-acetyl cysteine</keyword>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>